FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 731 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR A Combination of Durvalumab-Tremelimumab with mFOLFOX6 Is Tolerable with Promising Activity... August 29, 2023 Exercising Safely During Breast Cancer Treatment: What to Know October 27, 2022 Study Finds Most Women Who ‘Go Flat’ After Mastectomy Are Happy... January 16, 2021 3-in-1 Approach Helps Women in Rural Areas Get Cancer Screenings June 1, 2023 Load more HOT NEWS Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial DIY Mosquito Traps & Deterrents (That Really Work) After Being Told a Lump Was Benign, Teenager Learns She Has... A Better Biomarker for Cancer Immunotherapy?
